Rama Kandasamy1,2, Merryn Voysey1,2,3, Sarah Collins4, Guy Berbers5, Hannah Robinson1,2, Irene Noel1,2, Harri Hughes1,2, Susan Ndimah1,2, Katherine Gould6,7, Norman Fry4, Carmen Sheppard4, Shamez Ladhani4, Matthew D Snape1,2, Jason Hinds6,7, Andrew J Pollard1,2. 1. Oxford Vaccine Group, Department of Paediatrics, University of Oxford. 2. National Institute for Health Research Oxford Biomedical Research Centre, Oxford. 3. Nuffield Department of Primary Care Health Sciences, University of Oxford. 4. Public Health England, London, United Kingdom. 5. Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands. 6. Institute for Infection and Immunity, St George's, University of London. 7. BUGS Bioscience, London Bioscience Innovation Centre, United Kingdom.
Abstract
BACKGROUND: Following programmatic introduction of the 13-valent pneumococcal conjugate vaccine (PCV13), there is residual carriage and disease due to PCV13-covered serotypes. METHODS: PCV13-immunized children aged 13-48 months, N = 988, were enrolled between February 2014 and August 2015 ("late PCV13"), and had nasopharyngeal pneumococcal carriage compared with 7-valent pneumococcal conjugate vaccine (PCV7) immunized children, N = 567, enrolled between November 2010 and September 2011 ("early PCV13"). Nasopharyngeal pneumococci were molecular-serotyped by microarray. Invasive pneumococcal disease (IPD) cases were identified through enhanced national surveillance. RESULTS: Compared with PCV7-immunized children, carriage among PCV13-immunized children was significantly lower for serotypes 19A (odds ratio [OR], 0.08 [95% confidence interval {CI}, .02-.25]), 6C (OR, 0.11 [95% CI, .03-.32]), and 7F (8 vs 0 cases). IPD incidence in children <5 years was significantly lower for serotypes 1 (incidence rate ratio [IRR], 0.03 [95% CI, 0-.19]) and 7F (IRR, 0.13 [95% CI, .05-.36]) but not 19A (IRR, 0.6 [95% CI, .3-1.12]) or serotype 3 (IRR, 2.3 [95% CI, .86-6.15]) in the late PCV13 period than in the early PCV13 period. The most significant rises in IPD incidence were for serotypes 8, 12F, and 24F. CONCLUSIONS: PCV13 has reduced serotype 19A carriage among vaccinated children. We found no impact of PCV13 on serotype 3 carriage or disease, and emergence of non-PCV13-serotype disease.
BACKGROUND: Following programmatic introduction of the 13-valent pneumococcal conjugate vaccine (PCV13), there is residual carriage and disease due to PCV13-covered serotypes. METHODS: PCV13-immunized children aged 13-48 months, N = 988, were enrolled between February 2014 and August 2015 ("late PCV13"), and had nasopharyngeal pneumococcal carriage compared with 7-valent pneumococcal conjugate vaccine (PCV7) immunized children, N = 567, enrolled between November 2010 and September 2011 ("early PCV13"). Nasopharyngeal pneumococci were molecular-serotyped by microarray. Invasive pneumococcal disease (IPD) cases were identified through enhanced national surveillance. RESULTS: Compared with PCV7-immunized children, carriage among PCV13-immunized children was significantly lower for serotypes 19A (odds ratio [OR], 0.08 [95% confidence interval {CI}, .02-.25]), 6C (OR, 0.11 [95% CI, .03-.32]), and 7F (8 vs 0 cases). IPD incidence in children <5 years was significantly lower for serotypes 1 (incidence rate ratio [IRR], 0.03 [95% CI, 0-.19]) and 7F (IRR, 0.13 [95% CI, .05-.36]) but not 19A (IRR, 0.6 [95% CI, .3-1.12]) or serotype 3 (IRR, 2.3 [95% CI, .86-6.15]) in the late PCV13 period than in the early PCV13 period. The most significant rises in IPD incidence were for serotypes 8, 12F, and 24F. CONCLUSIONS: PCV13 has reduced serotype 19A carriage among vaccinated children. We found no impact of PCV13 on serotype 3 carriage or disease, and emergence of non-PCV13-serotype disease.
Authors: Feroze Ganaie; Karsten Maruhn; Chengxin Li; Richard J Porambo; Pernille L Elverdal; Chitrananda Abeygunwardana; Mark van der Linden; Jens Ø Duus; Carmen L Sheppard; Moon H Nahm Journal: J Clin Microbiol Date: 2021-06-18 Impact factor: 5.948
Authors: Feroze Ganaie; Jamil S Saad; Lesley McGee; Andries J van Tonder; Stephen D Bentley; Stephanie W Lo; Rebecca A Gladstone; Paul Turner; Jeremy D Keenan; Robert F Breiman; Moon H Nahm Journal: mBio Date: 2020-05-19 Impact factor: 7.867
Authors: Natalie Groves; Carmen L Sheppard; David Litt; Samuel Rose; Ana Silva; Nina Njoku; Sofia Rodrigues; Zahin Amin-Chowdhury; Nicholas Andrews; Shamez Ladhani; Norman K Fry Journal: Genes (Basel) Date: 2019-10-25 Impact factor: 4.096
Authors: George A Syrogiannopoulos; Ioanna N Grivea; Maria Moriondo; Francesco Nieddu; Aspasia N Michoula; Maria Rita Calabrese; Michael Anthracopoulos; Chiara Azzari Journal: Sci Rep Date: 2021-12-30 Impact factor: 4.379
Authors: Kenneth J Smith; Angela R Wateska; Mary Patricia Nowalk; Chyongchiou J Lin; Lee H Harrison; William Schaffner; Richard K Zimmerman Journal: Am J Prev Med Date: 2021-04-29 Impact factor: 6.604
Authors: Lorna Awo Renner; Effua Usuf; Nuredin Ibrahim Mohammed; Daniel Ansong; Thomas Dankwah; Jonas Tettey Kusah; Sandra Kwarteng Owusu; Marah Awunyo; Bernard Arhin; Yvonne Addo; John Asamoah; Joseph Nsiari-Muzeyi Biey; Peter Slyvanus Ndow; Archibald Worwui; Madikay Senghore; Bernard Ntsama; Jason M Mwenda; Stanley K Diamenu; Brenda Kwanbana Adams; Martin Antonio Journal: Clin Infect Dis Date: 2019-09-05 Impact factor: 9.079
Authors: Hannah Lawrence; Harry Pick; Vadsala Baskaran; Priya Daniel; Chamira Rodrigo; Deborah Ashton; Rochelle C Edwards-Pritchard; Carmen Sheppard; Seyi D Eletu; David Litt; Norman K Fry; Samuel Rose; Caroline Trotter; Tricia M McKeever; Wei Shen Lim Journal: PLoS Med Date: 2020-10-23 Impact factor: 11.069